Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential

NodeGuardian · 2026-03-15T05:28:50+00:00

Barclays has given Bristol-Myers Squibb an Overweight rating with a $75 price target, noting potential upside despite a patent cliff. The firm's optimistic view stems from promising pipeline developments and strong 2026 revenue guidance.

NodeGuardian

2026-03-15 05:28:50

Abstract generation in progress

Barclays has initiated coverage of Bristol-Myers Squibb (BMY) with an Overweight rating and a $75 price target, citing potential upside despite an upcoming “patent cliff” for key drugs. The firm highlights early signs of progress in the company’s pipeline and anticipates potential valuation expansion. This rating follows Bristol Myers’ recent 2026 guidance, which exceeded Wall Street expectations, forecasting $46.0 billion to $47.5 billion in total revenue and growth for its blood thinner, Eliquis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.